Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
A 26-year-old uses topical minoxidil, oral finasteride, and Nizoral shampoo for hair thinning and is considering microneedling but is unsure about the best approach. Users suggest using a 1.0mm dermaroller once a week, cautioning against overuse due to potential scarring, and some recommend combining microneedling with minoxidil for better absorption.
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
User shared 6-month progress using Fin, Min, Microneedling, Biotin, and Ketoconazole Shampoo for hair loss. They microneedle once a week, use 1.25 mg Fin daily, and apply topical Min twice a day.
Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.
The conversation is about the side effects of finasteride, including Post Finasteride Syndrome, with varied personal experiences and differing views on the credibility of information sources. Some participants also discuss using minoxidil as a hair loss treatment.
Jordan-Iliad has been using a combination of finasteride, minoxidil, stemoxydine, microneedling, saw palmetto, peppermint and jojoba oils, ketoconazole shampoo, and Purador shampoo/conditioner for 3 months to treat their hair loss with stunning results. They have also recently started taking oral minoxidil 1.25mg/day in hopes of achieving even better results over the next 3 months.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.
Microneedling may still be beneficial for those on oral minoxidil due to its effects on tissue repair and blood flow, not just absorption. Some users report mixed results, and the effectiveness of combining microneedling with oral treatments remains debated.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
Effective treatments for male pattern baldness include finasteride, dutasteride, and oral minoxidil. Non-effective approaches include oils, shampoos, serums, laser therapies, massages, vitamins, and microneedling.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
Hairfolliclestem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfolliclestem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Hair loss is linked to the loss of stem cells in hairfollicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hair growth.
PP405 targets hairfolliclestem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
Hairfollicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
Hairfollicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
PP405 cannot restore extracted hairfollicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
Inflammation plays a significant role in hairfollicle miniaturization and androgenetic alopecia, with treatments like ketoconazole shampoo, minoxidil, and finasteride being used to address it. Users discuss the benefits of anti-inflammatory treatments and peptides like KPV, alongside traditional hair loss treatments, to improve scalp health and hair quality.
PP405 is being discussed as a potential new approach to hair loss by targeting folliclestem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hairfolliclestem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
PP405 may revive dormant hairfollicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
Adipose fat cells and stem cells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hair growth.